H.C. Wainwright analyst Edward White lowered his price target for GlycoMimetics to $18 from $23 after the Phase 3 pivotal trial of rivipansel failed to meet its primary endpoint and key secondary efficacy endpoints. The analyst had a value of $4.63 per share for rivipansel in his price target. Investors should now focus on uproleselan, GlycoMimetics' wholly owned E-selectin inhibitor that targets endothelial cells to interrupt bone marrow cellular adhesion with leukemic cells, White tells investors in a research note. He keeps a Buy rating on GlycoMimetics shares.